Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering (Nasdaq: IMRX) reported Q1 2026 results and oncology pipeline updates. Cash, cash equivalents and marketable securities were $198.6 million, with an expected runway into 2029. Q1 R&D expenses were $10.6 million and net loss was $13.5 million, or $0.21 per share.
The pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer is now recruiting, with first patient dosing planned by mid-2026. New survival data from 55 first-line pancreatic cancer patients on atebimetinib + mGnP will be presented at ASCO 2026.
Immuneering (Nasdaq: IMRX) will present updated Phase 2a survival data for atebimetinib plus mGnP in first-line pancreatic cancer at the 2026 ASCO Annual Meeting.
The oral presentation covers an expanded cohort of 55 first-line patients and is scheduled for June 1, 2026, 1:15 PM CDT, presented by Dr. Peter Vu.
Immuneering (Nasdaq: IMRX) presented ctDNA data from 123 patients at AACR 2026 showing acquired MAPK pathway alterations were rare in atebimetinib-treated tumors. Findings suggest Deep Cyclic MEK inhibition may reduce MAPK-driven resistance and support first-line use in RAS-mutant cancers.
The company expects to dose the first patient in the pivotal Phase 3 MAPKeeper 301 in mid-2026 and to start a Phase 2 atebimetinib plus Libtayo trial in H2 2026.
Immuneering (Nasdaq: IMRX) said CEO Ben Zeskind will speak in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 3:45 p.m. ET. The session will be webcast live and archived in the company's Investor Relations Events & Presentations section.
Immuneering (Nasdaq: IMRX) will present molecular data at the AACR Annual Meeting (April 17-22, 2026) on April 20, 2026, reporting ctDNA analysis from ≥64 patients with RAS-mutant solid tumors treated with atebimetinib. The company says acquired MAPK pathway alterations were rarely seen, suggesting deeper, more durable MEK inhibition.
Poster 1873 (Poster Section 19) details how Deep Cyclic MEK inhibition aims to limit adaptive and acquired MAPK-axis resistance; the abstract will be on AACR and the poster on Immuneering’s publications page after presentation.
Immuneering (Nasdaq: IMRX) reported 64% overall survival at 12 months in an ongoing Phase 2a trial of atebimetinib + mGnP (N=34) with 13.4 months median follow-up.
The company is on track to dose the first patient in the pivotal Phase 3 MAPKeeper 301 mid-2026, completed FDA and EMA alignment, ended 2025 with $217.0M cash and expects runway into 2029. Full-year R&D was $42.0M; net loss was $56.0M (2025).
Immuneering (Nasdaq: IMRX) will present at the Leerink Global Healthcare Conference in Miami, March 9-11, 2026. CEO Ben Zeskind will deliver a fireside chat and hold 1x1 investor meetings on March 9, 2026, 3:40–4:10 pm ET.
The presentation will be webcast live and archived in the company's Investor Relations Events & Presentations section.
Immuneering (Nasdaq: IMRX) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, held virtually February 25-26, 2026.
Management, including CEO Ben Zeskind and CSO Brett Hall, will give a company presentation and hold 1x1 investor meetings on Thursday, February 26, 2026 at 10:00 am ET. The presentation will be webcast live and archived in the company’s Investor Relations Events & Presentations section.
Immuneering (Nasdaq: IMRX) reported updated Phase 2a data for atebimetinib + mGnP in first-line pancreatic cancer (N=34, median follow-up 13.4 months) showing 64% overall survival (OS) at 12 months with median OS not reached as of the December 15, 2025 cutoff. Key supportive results: 94% OS at 6 months, 83% at 9 months, ORR 39%, DCR 81%, mPFS 8.5 months. Safety showed Grade 3 neutropenia and anemia >10%; no new safety signals. Company plans to dose first patient in the MAPKeeper 301 pivotal Phase 3 trial in mid-2026 and to report expanded cohort data in 1H 2026.
Immuneering (Nasdaq: IMRX) will host a conference call and live webcast on January 7, 2026 at 4:00 p.m. ET to present updated 12-month overall survival (OS) results from its ongoing Phase 2a trial testing atebimetinib + modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.
The company said the webcast will be archived in its Investor Relations Events & Presentations section. Management highlighted confidence in atebimetinib’s potential to extend and improve patient survival and plans to discuss the 12-month OS update during the presentation.